Private Advisor Group’s Coherus Oncology CHRS Stock Holding History

Private Advisor Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-35,000	Closed	-$559K	–	2116
2021 Q4	$559K	Buy	+35,000	New	+$612K	﹤0.01%	1392

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Private Advisor Group's CHRS Position: Q1 2022 in Review

Private Advisor Group sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 35,000 shares — an estimated $559K sold.

Private Advisor Group first reported a position in CHRS in Q4 2021 and held it in 1 quarter. The position peaked at $559K in Q4 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

Private Advisor Group reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
Private Advisor Group sold 35,000 Coherus Oncology shares in Q1 2022, an estimated $559K.
Private Advisor Group first reported a position in Coherus Oncology in Q4 2021 and held it in 1 quarter.
Private Advisor Group's Coherus Oncology position peaked at $559K in Q4 2021.
183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Private Advisor Group's 13F filing for Q1 2022, filed 10 May 2022.